5-type HPV MRNA Versus 14-type HPV DNA Test: Test Performance, Over-diagnosis and Overtreatment in Triage of Women with Minor Cervical Lesions

Overview

Journal BMC Clin Pathol

Publisher Biomed Central

Date 2016 Jun 10

PMID 27279798

Citations 11

Authors

Bjorn Westre

Anita Giske

Hilde Guttormsen

Sveinung Wergeland Sorbye

Finn Egil Skjeldestad

Affiliations

Soon will be listed here.

Abstract

Background: Repeat cytology and HPV testing is used in triage of women with minor cytological lesions. The objective of this study was to evaluate 14-type HPV DNA and 5-type HPV mRNA testing in delayed triage of women with ASC-US/LSIL.

Methods: We compared a DNA test (Roche Cobas 4800) and an 5-type mRNA test (PreTect HPV-Proofer). In total 564 women were included in the study.

Results: The sensitivity among solved cases for CIN3+ were 100 % (15/15) for both tests. The sensitivity for CIN2+ of the HPV DNA test was 100 % (38/38) relative to 79 % (30/38) for the 5-type HPV mRNA test. The corresponding estimates of specificity for CIN2+ among solved cases were 84 % (393/466; 95 % CI: 81-88) and 91 % (451/498; 95 % CI: 88-93). The positive predictive values for CIN3+ were 13.5 % (15/111) for DNA+ and 19.5 % (15/77) for 5-type mRNA+. Significantly more women screened with 5-type mRNA than DNA returned to screening (81 % vs 71 %, p < 0.01). Subsequently, significantly fewer women were referred for colposcopy/biopsies/treatment (19 % (105/564) vs 29 % (165/564), p < 0.01).

Conclusions: 5-type HPV mRNA is more specific than 14-type HPV DNA in delayed triage of women with ASC-US/LSIL. The referral rate for colposcopy was 57 % higher for DNA+ relative to mRNA+ cases (165 vs 105), with the same detection rate of CIN3+, but the 5-type mRNA test had lower sensitivity for CIN2+. It is important to consider the trade-off between sensitivity and specificity of the diagnostic test when designing screening algorithms.

Citing Articles

Review of triage strategies for atypical squamous cells of undetermined significance among young women.

Cubaka Ntamushigo J, Motshedisi Sebitloane H Int J Gynaecol Obstet. 2024; 168(2):428-435.

PMID: 39268663 PMC: 11726148. DOI: 10.1002/ijgo.15915.

Enhancing Cervical Cancer Screening with 7-Type HPV mRNA E6/E7 Testing on Self-Collected Samples: Multicentric Insights from Mexico.

Flores C, Falang B, Gomez-Laguna L, Gutierrez G, Leon J, Uribe M Cancers (Basel). 2024; 16(13).

PMID: 39001547 PMC: 11240307. DOI: 10.3390/cancers16132485.

Enhancing Cervical Cancer Prevention in South African Women: Primary HPV mRNA Screening with Different Genotype Combinations.

Sorbye S, Falang B, Botha M, Snyman L, van der Merwe H, Visser C Cancers (Basel). 2023; 15(22).

PMID: 38001713 PMC: 10670851. DOI: 10.3390/cancers15225453.

Risk of Intraepithelial Neoplasia Grade 3 or Worse (CIN3+) among Women Examined by a 5-Type HPV mRNA Test during 2003 and 2004, Followed through 2015.

Rad A, Sorbye S, Tiwari S, Lochen M, Skjeldestad F Cancers (Basel). 2023; 15(12).

PMID: 37370716 PMC: 10296297. DOI: 10.3390/cancers15123106.

13-Type HPV DNA Test versus 5-Type HPV mRNA Test in Triage of Women Aged 25-33 Years with Minor Cytological Abnormalities-6 Years of Follow-Up.

Rad A, Sorbye S, Brenn T, Tiwari S, Lochen M, Skjeldestad F Int J Environ Res Public Health. 2023; 20(5).

PMID: 36901129 PMC: 10002392. DOI: 10.3390/ijerph20054119.

References

Koliopoulos G, Chrelias C, Pappas A, Makridima S, Kountouris E, Alepaki M . The diagnostic accuracy of two methods for E6&7 mRNA detection in women with minor cytological abnormalities. Acta Obstet Gynecol Scand. 2012; 91(7):794-801. DOI: 10.1111/j.1600-0412.2012.01414.x. View

Zappacosta R, Gatta D, Marinucci P, Capanna S, Lattanzio G, Caraceni D . Role of E6/E7 mRNA test in the diagnostic algorithm of HPV-positive patients showing ASCUS and LSIL: clinical and economic implications in a publicly financed healthcare system. Expert Rev Mol Diagn. 2014; 15(1):137-50. DOI: 10.1586/14737159.2015.961915. View

Arbyn M, Martin-Hirsch P, Buntinx F, Van Ranst M, Paraskevaidis E, Dillner J . Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate. J Cell Mol Med. 2009; 13(4):648-59. PMC: 3822872. DOI: 10.1111/j.1582-4934.2008.00631.x. View

Arbyn M, Roelens J, Cuschieri K, Cuzick J, Szarewski A, Ratnam S . The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy. Int J Cancer. 2012; 132(1):101-8. DOI: 10.1002/ijc.27636. View

de Sanjose S, Quint W, Alemany L, Geraets D, Klaustermeier J, Lloveras B . Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010; 11(11):1048-56. DOI: 10.1016/S1470-2045(10)70230-8. View

Ramakrishnan S, Partricia S, Mathan G . Overview of high-risk HPV's 16 and 18 infected cervical cancer: pathogenesis to prevention. Biomed Pharmacother. 2015; 70:103-10. DOI: 10.1016/j.biopha.2014.12.041. View

Arbyn M, Kyrgiou M, Simoens C, Raifu A, Koliopoulos G, Martin-Hirsch P . Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ. 2008; 337:a1284. PMC: 2544379. DOI: 10.1136/bmj.a1284. View

McCredie M, Sharples K, Paul C, Baranyai J, Medley G, Jones R . Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008; 9(5):425-34. DOI: 10.1016/S1470-2045(08)70103-7. View

Powell N, Hibbitts S, Boyde A, Newcombe R, Tristram A, Fiander A . The risk of cervical cancer associated with specific types of human papillomavirus: a case-control study in a UK population. Int J Cancer. 2010; 128(7):1676-82. DOI: 10.1002/ijc.25485. View

10.

Benevolo M, Vocaturo A, Caraceni D, French D, Rosini S, Zappacosta R . Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test. J Clin Microbiol. 2011; 49(7):2643-50. PMC: 3147832. DOI: 10.1128/JCM.02570-10. View

11.

Bruinsma F, Quinn M . The risk of preterm birth following treatment for precancerous changes in the cervix: a systematic review and meta-analysis. BJOG. 2011; 118(9):1031-41. DOI: 10.1111/j.1471-0528.2011.02944.x. View

12.

Sorbye S, Fismen S, Gutteberg T, Mortensen E . Triage of women with minor cervical lesions: data suggesting a "test and treat" approach for HPV E6/E7 mRNA testing. PLoS One. 2010; 5(9):e12724. PMC: 2938337. DOI: 10.1371/journal.pone.0012724. View

13.

Sorbye S, Fismen S, Gutteberg T, Mortensen E . HPV mRNA test in women with minor cervical lesions: experience of the University Hospital of North Norway. J Virol Methods. 2010; 169(1):219-22. DOI: 10.1016/j.jviromet.2010.07.011. View

14.

Nygard J, Skare G, Thoresen S . The cervical cancer screening programme in Norway, 1992-2000: changes in Pap smear coverage and incidence of cervical cancer. J Med Screen. 2002; 9(2):86-91. DOI: 10.1136/jms.9.2.86. View

15.

Nygard M, Roysland K, Campbell S, Dillner J . Comparative effectiveness study on human papillomavirus detection methods used in the cervical cancer screening programme. BMJ Open. 2014; 4(1):e003460. PMC: 3902315. DOI: 10.1136/bmjopen-2013-003460. View

16.

Saslow D, Solomon D, Lawson H, Killackey M, Kulasingam S, Cain J . American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012; 137(4):516-42. DOI: 10.1309/AJCPTGD94EVRSJCG. View

17.

Ratnam S, Coutlee F, Fontaine D, Bentley J, Escott N, Ghatage P . Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer. J Clin Microbiol. 2010; 48(8):2779-85. PMC: 2916571. DOI: 10.1128/JCM.00382-10. View

18.

Arbyn M, Castellsague X, de Sanjose S, Bruni L, Saraiya M, Bray F . Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011; 22(12):2675-2686. DOI: 10.1093/annonc/mdr015. View

19.

Tjalma W, Fiander A, Reich O, Powell N, Nowakowski A, Kirschner B . Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. Int J Cancer. 2012; 132(4):854-67. DOI: 10.1002/ijc.27713. View

20.

Verdoodt F, Szarewski A, Halfon P, Cuschieri K, Arbyn M . Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types. Cancer Cytopathol. 2013; 121(12):675-87. DOI: 10.1002/cncy.21325. View